Top Page
CANbridge Pharmaceuticals Inc.
(1228)
CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)
CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model
CANbridge Pharmaceuticals Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 85.10M | 102.87M | 78.97M | 31.16M | 12.03M |
| Gross Profit | 54.30M | 64.16M | 48.89M | 18.78M | 6.88M |
| EBITDA | -328.69M | -341.43M | -454.63M | -1.06B | -824.41M |
| Net Income | -442.62M | -378.84M | -483.48M | -1.08B | -846.04M |
Balance Sheet | |||||
| Total Assets | 116.81M | 395.36M | 702.04M | 892.52M | 586.36M |
| Cash, Cash Equivalents and Short-Term Investments | 10.50M | 137.49M | 451.16M | 745.82M | 360.80M |
| Total Debt | 135.78M | 141.93M | 155.28M | 52.10M | 46.90M |
| Total Liabilities | 591.30M | 435.15M | 393.49M | 199.13M | 2.33B |
| Stockholders Equity | -474.49M | -39.79M | 308.56M | 693.39M | -1.75B |
Cash Flow | |||||
| Free Cash Flow | -122.50M | -319.09M | -315.76M | -592.40M | -305.13M |
| Operating Cash Flow | -122.39M | -278.23M | -280.98M | -587.07M | -151.65M |
| Investing Cash Flow | 13.93M | -26.86M | -34.79M | 126.09M | -153.48M |
| Financing Cash Flow | -18.57M | -28.02M | -20.70M | 854.31M | 679.26M |
CANbridge Pharmaceuticals Inc. Technical Analysis
CANbridge Pharmaceuticals Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$1.11B | ― | -266.90% | ― | ― | 31.23% | |
54 Neutral | HK$2.38B | ― | -41.34% | ― | -10.78% | 24.88% | |
53 Neutral | HK$1.90B | ― | -32.59% | ― | -79.65% | 37.50% | |
51 Neutral | $7.77B | -0.12 | -39.78% | 2.21% | 22.68% | -1.42% | |
49 Neutral | HK$1.01B | ― | ― | -1.73% | -689.53% | ||
44 Neutral | HK$862.42M | ― | ― | -18.57% | -14.06% | ||
36 Underperform | HK$1.12B | ― | -41.20% | ― | ― | 85.29% |
CANbridge Pharmaceuticals Inc. Corporate Events
CANbridge Pharmaceuticals Inc. has entered into a strategic collaboration and exclusive commercial services agreement with a subsidiary of Qingdao Baheal Medical Inc. This agreement appoints Baheal as the exclusive Contract Sales Organization for promoting CANbridge’s products in mainland China, Hong Kong, and Macau. The agreement, which is of a revenue nature and part of the company’s ordinary business activities, does not constitute a notifiable or connected transaction under Hong Kong’s listing rules. This strategic move is expected to enhance CANbridge’s market presence in the Greater China region.
CANbridge Pharmaceuticals Inc. has entered into a Subscription Agreement to issue 74,971,468 new shares at a price of HK$1.34 per share, representing a discount to the last trading day’s closing price but a premium to the average closing price over the past five days. The gross proceeds from this subscription are expected to be over HK$100 million, with net proceeds earmarked for research and development, marketing, loan repayment, and daily operations. The subscription is subject to approval from the Stock Exchange, and trading of the company’s shares was temporarily halted pending this announcement.
CANbridge Pharmaceuticals Inc. has announced a trading halt on its shares on the Hong Kong Stock Exchange, effective from August 12, 2025. This halt is pending the release of an announcement containing inside information, which may have significant implications for the company’s operations and its stakeholders.
CANbridge Pharmaceuticals Inc. has announced a change in its principal place of business in Hong Kong, moving to the 40th Floor, Dah Sing Financial Centre, effective July 11, 2025. This relocation reflects the company’s strategic efforts to enhance its operational capabilities and strengthen its presence in the region, potentially impacting its stakeholders by positioning the company for future growth and development.
CANbridge Pharmaceuticals Inc. has announced the appointment of Ms. Zhao Wei as a non-executive director and a member of the remuneration committee, effective June 30, 2025. This appointment is part of a broader change in the composition of the board committees, which also includes the addition of Dr. Lan Hu to the Nomination and Corporate Governance Committee to meet gender diversity requirements. These changes are expected to enhance the company’s governance and strategic direction.
CANbridge Pharmaceuticals Inc. has announced the composition of its board of directors and their respective roles within the company. This update highlights the leadership structure and the committees each director is involved in, reflecting the company’s commitment to strong governance and strategic oversight.
CANbridge Pharmaceuticals Inc. has established a Nomination and Corporate Governance Committee, as resolved by its Board of Directors on June 21, 2021. This move is part of the company’s efforts to enhance its corporate governance structure, which could potentially strengthen its industry positioning and provide better oversight for stakeholders.
CANbridge Pharmaceuticals Inc. announced that all resolutions, except one which was withdrawn, were approved at their Annual General Meeting held on June 27, 2025. The resolutions included re-electing directors, authorizing board remuneration, reappointing the auditor, and granting mandates for share issuance and repurchase. This outcome reflects strong shareholder support and positions the company for continued strategic initiatives in its industry.
CANbridge Pharmaceuticals Inc. announced the resignation of Dr. Fangxin Li as a non-executive director and member of the remuneration committee, effective June 25, 2025, due to changes in his work arrangements. This resignation has resulted in the remuneration committee falling below its required number of members, prompting the company to seek a suitable replacement. Additionally, the company has withdrawn an ordinary resolution related to Dr. Li’s proposed re-election at the upcoming annual general meeting, while all other meeting details remain unchanged.
CANbridge Pharmaceuticals Inc. has announced that its annual general meeting (AGM) will be held virtually on June 27, 2025. The meeting will cover several key resolutions, including the re-election of board members, the re-appointment of the company’s auditor, and the authorization for directors to issue additional shares. These decisions are crucial for the company’s governance and financial strategies, potentially impacting its market operations and shareholder value.
CANbridge Pharmaceuticals Inc. announced that its product, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval in the PRC for treating type I and III Gaucher disease. This approval marks a significant milestone as Gaurunning is the first domestically developed enzyme replacement therapy for these conditions, potentially enhancing medication accessibility for patients in China and strengthening CANbridge’s position in the rare disease treatment market.